Shots:

• The Validation study involves assessing of MSProDiscuss in 198 patients with relapsing-remitting MS (RRMS)- secondary progressive MS (SPMS) or a suspected transition to SPMS across the US- Canada & Germany
• The validation study resulted that MSProDiscuss can differentiate between RRMS and SPMS- utilizing information from the patient’s symptoms experienced in the 6mos.- which were further converted into visual output through the algorithm providing physicians with better insights- presented at AAN'19
• MSProDiscuss is an algorithm-based tool- supporting & facilitating physicians & patients to evaluate the risk of transitioning RRMS to SPMS. The tool is housed on neuro-compass- the educational MS site- developed in collaboration with Adelphi Value with its expected WW availability in H1’20

Ref: Novartis | Image: Recruiting Blogs